Chopra, Neha
Tovey, Holly
Pearson, Alex http://orcid.org/0000-0002-5854-193X
Cutts, Ros
Toms, Christy
Proszek, Paula
Hubank, Michael
Dowsett, Mitch
Dodson, Andrew
Daley, Frances
Kriplani, Divya
Gevensleben, Heidi
Davies, Helen Ruth
Degasperi, Andrea http://orcid.org/0000-0001-6879-0596
Roylance, Rebecca
Chan, Stephen
Tutt, Andrew
Skene, Anthony
Evans, Abigail
Bliss, Judith M.
Nik-Zainal, Serena http://orcid.org/0000-0001-5054-1727
Turner, Nicholas C.
Funding for this research was provided by:
Breast Cancer Now
Cancer Research UK (C38317/A24043, A15777, C60100/A23916)
Wellcome Trust (WT100183MA)
Article History
Received: 18 July 2019
Accepted: 3 April 2020
First Online: 29 May 2020
Competing interests
: N.T., J.M.B., H.T. and C.T. report research grants and non-financial support in the form of study drug provision and distribution from Clovis Oncology Inc., during the conduct of the study. N.T. reports advisory board Honoraria from AstraZeneca, Bristol-Myers Squibb, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Roche/Genentech, Tesaro, Bicycle Therapeutics and research funding from Astra Zeneca, BioRad, Pfizer, Roche/Genentech and Guardant Health, outside the submitted work. J.M.B. reports grants and non-financial support from AstraZeneca, Merck Sharpe & Dohme, Puma Biotechnology and Janssen-Cilag, grants, non-financial support and travel support from Pfizer and grants from Medivation, Novartis and Roche outside the submitted work. M.H. reports Honoraria or research funding from Boehringer Ingelheim, Roche Diagnostics, Bristol Myers Squibb, Guardant Health, Celgene, Eli Lilley outside of the submitted work. R.R. reports Honorarium from Pfizer. A.T. reports benefits from ICR’s Inventors Scheme associated with patents for one of the PARP inhibitors in BRCA1/2 associated cancers. A.T. also reports Honoraria from Pfizer, Vertex, Prime Oncology, Artios, honoraria and stock in InBiomotion, honoraria and financial support from AstraZeneca, Medivation, Myriad Genetics, Merck Serono. S.N.Z. and H.D. are inventors on a patent application (WO2017191074A1) for HRDetect. S.N.Z. reports advisory board honoraria from Astra Zeneca and Artios Pharma. M.D. reports advisory board Honoraria from GTx, Radius, Orion and G1therapeutics, lectures fees from Myriad and Nanostring, research funding from Pfizer and Radius and income from the Institute of Cancer Research’s Rewards for Inventors Scheme (Abiraterone) outside the submitted work. All other authors declare no competing interests.